Dr. Jong Kim currently serves as the president, CEO and a director of Inovio Pharmaceuticals.
Inovio is a pharmaceutical company that develops treatments for cancer and other chronic infectious diseases. The company, which spun out of the University of Pennsylvania Medical School and was known as VGX Pharmaceuticals until 2009, currently has around 300 employees and a market cap of $500 million.
Dr. Kim co-founded VGX in 2000 and served as its president and CEO until the time of its acquisition by Inovio in 2009, during which time he assumed the roles of president, CEO and director. In his current role, he is working to develop vaccines for developed markets and developing-world markets to combat the world’s top infectious diseases.
Prior to his career at VGX and Inovio, Dr. Kim spent eight years with Merck & Company Inc. There he led efforts to manufacture and develop a variety of FDA-approved products and developmental therapeutics, including FDA-approved vaccines for hepatitis and developmental vaccines and therapies for HIV AIDS.
Drawing on his background as an immunologist, Dr. Kim has worked to publish over 100 peer-reviewed scientific papers, holds several patents, and sits on the editorial boards of various scientific review panels. He has been recognized for his contributions to the scientific community by various institutions, with recognition as one of the world’s Top 100 Young Innovators by Technology Review Magazine in 2002, one of the Philadelphia Business Journal’s 40 under 40, and as Ernst & Young’s Entrepreneur of the Year for Greater Philadelphia in 2015.
Dr. Kim currently sits on the boards of the Council of Korean Americans and the International Vaccine Institute. He is also part of the inaugural class of the Health Innovators Fellowship at the Aspen Institute. As a native of South Korea, he has worked with the World Economic Forum and the Global Agenda Council on Korea to develop new vaccines to protect the world’s poorest populations.
Dr. Kim holds a Ph.D. in biochemical engineering from the University of Pennsylvania and an M.B.A. in finance from the Wharton School. He received his undergraduate degree from MIT.
What is Jong Joseph Kim's net worth?
The estimated net worth of Jong Joseph Kim is at least $9.28 million as of February 1st, 2021. Dr. Kim owns 1,078,313 shares of Inovio Pharmaceuticals stock worth more than $9,284,275 as of August 3rd. This net worth estimate does not reflect any other assets that Dr. Kim may own.
How do I contact Jong Joseph Kim?
The corporate mailing address for Dr. Kim and other Inovio Pharmaceuticals executives is 660 W. GERMANTOWN PIKE SUITE 110., PLYMOUTH MEETING PA, 19462. Inovio Pharmaceuticals can also be reached via phone at 858-410-3134 and via email at [email protected]
Has Jong Joseph Kim been buying or selling shares of Inovio Pharmaceuticals?
Jong Joseph Kim has not been actively trading shares of Inovio Pharmaceuticals within the last three months. Most recently, Jong Joseph Kim sold 62,500 shares of the business's stock in a transaction on Wednesday, February 3rd. The shares were sold at an average price of $14.24, for a transaction totalling $890,000.00. Following the completion of the sale, the chief executive officer now directly owns 1,078,313 shares of the company's stock, valued at $15,355,177.12.
Who are Inovio Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Inovio Pharmaceuticals?
In the last twelve months, insiders at the biopharmaceutical company sold shares 20 times. They sold a total of 458,338 shares worth mmore than $5,630,680.22. The most recent insider tranaction occured on June, 09th when Jacqueline Elizabeth Shea COO bought 38,535 shares worth more than $385,735.35. Insiders at Inovio Pharmaceuticals own 2.9 % of the company.
Information on this page was last updated on 6/9/2021.